Literature DB >> 12166843

Emergency endovascular treatment of thoracic aortic rupture in three accident victims with multiple injuries.

Denise Nio1, Patrick M Vos, Bas A J M de Mol, Kees J Ponsen, Jim A Reekers, Ron Balm.   

Abstract

PURPOSE: To report an experience with emergency endovascular treatment of traumatic thoracic aortic ruptures in multi-injured patients. CASE REPORTS: Three victims of motor vehicle accidents with multiple head, chest, and abdominal injuries in addition to fractures were treated urgently for thoracic aortic lacerations with transluminal placement of an endovascular graft during the initial emergent laparotomy. In all cases, ruptured visceral organs were treated first and the abdomen closed. Femoral artery access was gained through a cutdown, and the endografts were delivered with no systemic heparinization. The endovascular component of the surgical session took approximately 50 minutes. All patients survived to discharge. Two patients are alive at 5 and 12 months with sustained endovascular exclusion of the pseudoaneurysm, but one patient with severe brain damage died 9 months after treatment from respiratory insufficiency.
CONCLUSIONS: Acute endovascular treatment of thoracic aortic ruptures is feasible and has the advantage of avoiding thoracotomy in otherwise severely injured patients.

Entities:  

Mesh:

Year:  2002        PMID: 12166843

Source DB:  PubMed          Journal:  J Endovasc Ther        ISSN: 1526-6028            Impact factor:   3.487


  2 in total

1.  Combined trauma laparotomy and endovascular repair of thoracic aortic injury.

Authors:  Thomas L Forbes; Neil G Parry
Journal:  Can J Surg       Date:  2004-10       Impact factor: 2.089

2.  MRI assessment of thoracic stent grafts after emergency implantation in multi trauma patients: a feasibility study.

Authors:  Volker Rasche; Alexander Oberhuber; Stephan Trumpp; Axel Bornstedt; Karl-Heinz Orend; Nico Merkle; Wolfgang Rottbauer; Martin Hoffmann
Journal:  Eur Radiol       Date:  2011-02-18       Impact factor: 5.315

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.